Phase 1 N=34 A Dose-escalation Study to Investigate Safety and Toleration of OZ439
Malaria
Primary: OZ439 Cmax — 672; 1720; 1870 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=22 Bioavailability Study of Oral OZ439 Prototype Formulations Administered With Piperaquine Phosphate (PQP)
Malaria
Primary: OZ439 AUC(0-168h) — 8780; 10300; 9460 ng*h/mL
Phase 1 N=13 An [^11C]T-773 Positron Emission Tomography (PET) Study to Determine Phosphodiesterase10A Occupancy by TAK-063
Healthy Volunteers
Primary: Phosphodiesterase 10A (PDE10A) Occupancy of Brain Regions With [^11C]T-773 at 3 Hours Following a Single Dose of TAK-063 — 14.400; 26.650; 39.333; 53.633 Percent
Phase 1 N=42 Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food
Healthy
Primary: Empagliflozin: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz) — 5990; 5720 nmol*h/L
Phase 1 N=49 MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects
Healthy
Primary: Safety and Tolerability of N91115 — 9; 6; 6; 6 participants
Phase 1 N=18 Study of Postoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients
Rectal Neoplasms
Primary: Dose Related Toxicity — 1; 0; 0; 3 event
Phase 1 N=27 Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer
Stomach Neoplasms
Primary: Number of Participants With First Cycle Dose-limiting Toxicities (DLTs) — 2; 1; 3 participants
Phase 1 N=38 Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies
Hodgkin's Disease · Non-Hodgkin's Lymphoma
Primary: The Maximum Tolerated Dose (MTD) of Niacinamide in the Combination of Vorinostat and Niacinamide — 100 mg/kg
Phase 1 N=16 Safety Study of Transvenous Limb Perfusion in Human Muscular Dystrophy
Muscular Dystrophies · Duchenne Muscular Dystrophy · Becker Muscular Dystrophy
Primary: Muscle, Nerve, or Vascular Damage — 16 participants
Phase 1 N=28 E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)
Non-small-cell Lung Cancer
Primary: Maximum Tolerated Dose (MTD) — 4 mg BID
Phase 1 N=9 A Study of E7080 in Subjects With Solid Tumor
Cancer
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0 Participants
Phase 1 N=27 An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors
Cancer: Solid Tumors
Primary: Maximum Tolerable Dose (MTD) of E7080 Repeatedly Administered Twice a Day — 13 mg BID
Phase 1 N=8 Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets
Gastroesophageal Reflux Disease · Erosive Esophagitis · Heartburn
Primary: Time to In-Vivo Disintegration of Dexlansoprazole 30 mg Orally Disintegrating Tablets — 36.0 Seconds
Phase 1 N=10 Heat Retention Head Wrap Use for Re-warming of Infants Requiring Cardio-Pulmonary Bypass
Impaired Thermoregulation
Primary: Head Wrap Feasibility — 100 percentage of respondents
Phase 1 N=36 Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto®.
Healthy
Primary: Linagliptin: AUC 0-72 (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to 72 Hours) — 293; 288 nmol*h/L — p=<0.0001